Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of MK-1167 in Healthy Elderly Participants
NCT06625840Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-1167 in Alzheimer's disease (AD) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing an Adverse Event (AE) up to 41 days, Number of Participants Discontinuing Study Treatment due to an AE up to 16 days and 7 more. Started Sep 2023; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06625840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625840.